Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy

Rationale: Lu-177-PSMA-617 radioligand therapy (RLT) is currently under approval for treatment of metastatic castration resistant prostate cancer (mCRPC) patients with late stage disease. However, previous studies demonstrated both heterogeneity of prostate specific membrane antigen (PSMA) expressio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Theranostics
Main Authors: Kessel, Katharina, Seifert, Robert, Weckesser, Matthias, Roll, Wolfgang, Humberg, Verena, Schlack, Katrin, Bögemann, Martin, Bernemann, Christof, Rahbar, Kambiz
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359074/
https://ncbi.nlm.nih.gov/pubmed/32685010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.44556
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados